References
- Arnum PV. Tracking growth in biologics. Pharm Technol. 2013;37(2):16.
- Monoclonal antibodies (mAbs) market size | industry report, 2013–2024. [Cited 2016 Nov 12]. Available from: http://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
- Vugmeyster Y. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem. 2012;3(4):73.
- Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192–1198.
- Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–39.
- Shankar G, Shores E, Wagner C, et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006;24(6):274–280.
- Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1–2):1–9.
- Büttel IC, Chamberlain P, Chowers Y, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals. 2011;39(2):100–109.
- PhRMA | chart packs. PhRMA Chart Packs. [Cited 2016 Mar 21]. Available from: http://chartpack.phrma.org/biophrma-chartpack/biopharmaceuticals-in-perspective-2015
- Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor | pfizer: one of the world’s premier biopharmaceutical companies. [Cited 2017 Feb 15]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor
- Rup B, Pallardy M, Sikkema D, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385–400.
- ABIRISK. [Cited 2019 May 13]. Available from: http://www.abirisk.eu/press_release.html
- Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–338.
- Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555–561.
- Kelderman S, Schumacher TNM, Haanen JBAG. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol. 2014;8(6):1132–1139.
- Krishna M, Nadler SG. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol. 2016;7:21.
- Bio-Rad. Anti-idiotypic antibodies. Bio-Rad. Cited 2020 Jun 15. Available from: https://www.bio-rad-antibodies.com/anti-idiotypic-antibody.html
- Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase subtilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340(2):228–236.
- C. for D. E. and Research. Immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection. U.S. Food and Drug Administration. 2020. [Cited 2020 May 27]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug
- Approaches to mitigate the unwanted immunogenicity of therapeutic proteins. eBSCOhost. [Cited 2020 May 27]. Available from: http://web.a.ebscohost.com.ezproxy.lib.utah.edu/ehost/detail/detail?vid=0&sid=5d728ada-2043-4fba-bb21-87b62bb8815b%40sessionmgr4007&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#AN=28083796&db=mdc
- Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
- Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–673.
- Full article: development and characterization of an anti-rituximab monoclonal antibody panel. [Cited 2020 May 27]. Available from: https://www.tandfonline.com/doi/full/10.1080/19420862.2018.1424610
- Guidance for industry immunogenicity assessment for therapeutic protein products. Food Drug Admin. 2014;79(157):47649-47650.
- Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 2006;58(5–6):640–656.
- Parenky A, Myler H, Amaravadi L, et al. New FDA draft guidance on immunogenicity. AAPS J. 2014;16(3):499–503.
- Brooks B. The importance of epitope binning for biological drug discovery. Curr Drug Discov Technol. 2014;11(2):109-112.
- Abdiche YN, Lindquist KC, Pinkerton A, et al. Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis. Anal Biochem. 2011;411(1):139–151.
- Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008;17(8):1326–1335.
- Abdiche YN, Malashock DS, Pinkerton A, et al. Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. Anal Biochem. 2009;386(2):172–180.
- Ditto N, Brooks B. The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery. Expert Opin Drug Deliv. 2016;11(10):925–937.
- Abdiche YN, Miles A, Eckman J, et al. High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity. PLoS One. 2014;9(3):e92451.
- Abdiche YN, Harriman R, Deng X, et al. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. mAbs. 2016;8(2):264–277.
- Leach MW, Rottman JB, Hock MB, et al. Continuing Education Course# 4: immunogenicity/Hypersensitivity of Biologics. 2013.
- Sazonovs A, Kennedy N, Moutsianas L, et al. HLA-DQA1* 05 is associated with the development of antibodies to anti-TNF therapy. BioRxiv. 2018;410035.
- Benucci M, Damiani A, Li Gobbi F, et al. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biol Targets Ther. 2018;12:37–41.
- Wysocki T, Olesińska M, Paradowska-Gorycka A. Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice. Cells. 2020;9(5):1127.
- Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158(1):189–199.
- Ingenhoven K, Kramer D, Jensen PE, et al. Development and validation of an enzyme-linked immunosorbent assay for the detection of binding anti-drug antibodies against interferon beta. Front Neurol. 2017;8. DOI:10.3389/fneur.2017.00305.
- Link J, Lundkvist Ryner M, Fink K, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS One. 2014;9(3):e90479.
- Mazor R, Crown D, Addissie S, et al. Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cell Mol Immunol. 2017;14(5):432–442.
- Gorovits B. Immunogenicity: prediction, detection and effective assay development. Bioanalysis. 2010;2(9):1539–1545.